Companies · Biotech / Pharma

Greenlight Biosciences Inc.

Medford · Biotech / Pharma · refined from filed group “Other Technology

Diligence memoA one-page analyst read on Greenlight Biosciences Inc. — recommendation, valuation, rhythm, risks.
$179.4M
Total raised · real
5
Rounds
2.6×
Latest step-up
Top 3%
Sector rank · raised
Series D+
Latest stage · inferred · Mon Jun 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Greenlight Biosciences Inc. has raised $179M over 5 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Dormant
  • Last raise 6.0 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Greenlight Biosciences Inc. is one of 227 Biotech / Pharma companies tracked from Medford. By capital raised it ranks among the largest (ahead of 98% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
19
Investors (latest)
2020-06-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2013-07-29 Raised $8.0M (real) Modeled valuation $270M (est)$8.0M$270MSeries A2013Series A · 2013-07-29 Raised $7.0M (real) Modeled valuation $235M (est)$7.0M$235MSeries A2013Series B · 2015-06-01 Raised $20M (real) Modeled valuation $736M (est)$20M$736MSeries B2015Series B · 2017-08-31 Raised $10.0M (real) Modeled valuation $368M (est)$10.0M$368MSeries B2017Series B · 2018-12-07 Raised $39M (real) Modeled valuation $1.4B (est)$39M$1.4BSeries B2018Series D+ · 2020-06-15 Raised $103M (real) Modeled valuation $3.9B (est)$103M$3.9BSeries D+2020+$7.0M+$20M+$10.0M+$39M+$103MCumulative $186M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.0M · 2013
Series A extension$7.0M · 2013
Series B$20.0M · 2015
Series B extension$10.0M · 2017
Series B extension$38.7M · 2018
Series D+$102.5M · 2020no Series C on file

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$3.9B
Base estimate est.
$476.5M
Conservative case
$8.6B
Upside case
$854.6M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Series A · modeled $269.5M · 2013-07-292013Series A · modeled $234.5M · 2013-07-29Series B · modeled $735.9M · 2015-06-01Series B · modeled $367.8M · 2017-08-31Series B · modeled $1.4B · 2018-12-07Series D+ · modeled $3.9B · 2020-06-152020
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
70%
Survival probability
56% low · 77% high
1.37×/yr
Annual markup
1.53×/yr upside case
6.0 yr
Elapsed time used
6.0 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
17 mo
Avg between rounds
$26.1M/yr
Capital velocity
12.9 yr
On record since
2013
First round
6
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 32× above median
This company$179.4M
Sector median$5.6M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 2.0× above median
This company$102.5M
Sector median$51.0M
Modeled value — vs sector median (estimate, all stages) 128× above median
This company$3.9B
Sector median$30.5M

Raised more than 98% of sector peers (real $). Modeled value above 100% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.0M2013-07-29$36.6M$269.5M85%
Series A$7.0M2013-07-29$31.8M$234.5M85%
Series B$20.0M2015-06-01$111.2M$735.9M85%
Series B$10.0M2017-08-31$55.6M$367.8M90%
Series B$38.7M2018-12-07$215.3M$1.4B90%
Series D+$102.5M2020-06-15$854.6M$3.9B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.0M2013-07-29
    • First recorded raise — entered as Series A.
    • 3 investors on this round.
  2. Series A$7.0M2013-07-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • Switched to Rule 06 (was Rule 506(b)).
    • 2 investors on this round.
  3. Series B$20.0M2015-06-01
    • Raised 22 mo later, in step with the ~15 mo sector norm.
    • Round 2.9× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 7 investors on this round.
  4. Series B$10.0M2017-08-31
    • Raised again after 27 mo — slower than the ~15 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  5. Series B$38.7M2018-12-07
    • Raised 15 mo later, in step with the ~15 mo sector norm.
    • Round 3.9× larger than the prior — scaling up.
    • 15 investors on this round.
  6. Series D+$102.5M2020-06-15
    • Raised 18 mo later, in step with the ~15 mo sector norm.
    • Round 2.6× larger than the prior — scaling up.
    • 19 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~17mo cadence
$271.4M
Modeled next size est.range $176.4M$434.2M
2.6×
Last step-up
$26.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Matthew Walker10 other2018-12
Jonathan Fleming8 other2013-07
Michael Liang8 other2020-06
David Furneaux7 other2013-07
Jason Dinges7 other2020-06
Ganesh Kishore6 other2017-08
Andrey Zarur5 other2013-07
Eric O'Brien5 other2017-08
Charles Cooney3 other2013-07
Charles L. Cooney3 other2015-06
Martha Schlicher3 other2018-12
Neil Renninger3 other2013-07
Greg Lucier1 other2013-07
David L. Furneaux2015-06
Ganesh L. Kishore2015-06
James L. Swartz2015-06
James Swartz2013-07
Jonathan L. Fleming2015-06
Marta L. Ortega-Valle2015-06
Marta Ortega-Valle2017-08
Neil L. Renninger2015-06
William L. Blake2015-06
Registry & provenance

Greenlight Biosciences Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1583880
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lumicell, Inc.BiotechnologySeries D+$331.1M$1.7Bnetwork2 shared operators · same stage
Alto Pharmacy Holdings, Inc.Biotech / PharmaSeries D+$169.7M$3.1Bsame sector · same stage
Ventyx Biosciences, Inc.Biotech / PharmaSeries D+$192.3M$273.5Msame sector · same stage
Colossal Biosciences Inc.Biotech / PharmaSeries D+$162.6M$2.8Bsame sector · same stage
Seismic Therapeutic, Inc.Biotech / PharmaSeries D+$146.3M$1.9Bsame sector · same stage
Iterative Scopes, Inc.BiotechnologySeries D+$172.1M$3.6Bnetwork1 shared operator · same stage
Vedanta Biosciences, Inc.Biotech / PharmaSeries D+$240.3M$2.0Bsame sector · same stage
Elektrofi, Inc.BiotechnologySeries D+$154.8M$1.2Bnetwork1 shared operator · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Greenlight Medical, Inc.HealthtechSeed$32.6M92%
Light Bio, Inc.Biotech / PharmaSeed$82.3M90%
ClearLight Biotechnologies, LLCBiotech / PharmaSeed$113.9M89%
Greenlight Health Data Solutions, Inc.HealthtechSeries A$17.8M89%
Green Star Biosciences Inc.Biotech / PharmaPre-Seed$12.8M87%
Green Light Beverage, Inc.Food & BeverageSeries B$68.9M85%
growPack Bio LLCBiotech / PharmaSeed$26.3M84%
Green Light Labs, Inc.Software / TechPre-Seed$4.2M84%
Frequently asked
How much funding has Greenlight Biosciences Inc. raised?
Greenlight Biosciences Inc. has raised approximately $179.4M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Greenlight Biosciences Inc.'s estimated valuation?
Provath's modeled valuation for Greenlight Biosciences Inc. is approximately $3.9B (modeled range $476.5M–$8.6B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Greenlight Biosciences Inc. at?
Greenlight Biosciences Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Mon Jun 15.
What does Greenlight Biosciences Inc. do and where is it based?
Greenlight Biosciences Inc. operates in the Biotech / Pharma sector, based in Medford.
Explore related

See where Greenlight Biosciences Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Greenlight Biosciences Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.